164 results on '"Hartung, Ingo V."'
Search Results
2. The experiment is the limit
3. Workflow for E3 Ligase Ligand Validation for PROTAC Development.
4. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening
5. Identifying palladium culprits in amine catalysis
6. Rules were made to be broken
7. Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor.
8. Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T‑Cell Immunity against Cancer.
9. Supplementary Data from Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation
10. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
11. The 17th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders
12. Data from Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation
13. Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation
14. Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
15. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative:Hit Generation
16. European Medicinal Chemistry Leaders in Industry (EMCL) – On the Status and Future of Medicinal Chemistry Research in Europe**
17. Identification and characterization of the new generation sGC stimulator BAY 1165747 (BAY‐747) designed for the treatment of resistant hypertension
18. New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension
19. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation
20. Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design
21. Target 2035 – an update on private sector contributions
22. The 17th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders.
23. Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY‐747 designed for the treatment of resistant hypertension.
24. Target 2035 – update on the quest for a probe for every protein
25. sj-pdf-1-jbx-10.1177_24725552211019409 – Supplemental material for Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening
26. No shortcuts to SARS-CoV-2 antivirals
27. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative:Phenotypic Drug Discovery
28. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery
29. Target 2035 – an update on private sector contributions
30. Amine-Catalysed Suzuki–Miyaura-Type Coupling? the Identification and Isolation of the Palladium Culprits.
31. Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics**
32. Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics
33. The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes
34. Synthetic studies toward the disorazoles: synthesis of a masked northern half of disorazole D 1 and a cyclopropane analog of the masked northern half of disorazole A 1
35. Abstract 1288: Blocking tumor-associated immune suppression with BAY-218, a novel, selective aryl hydrocarbon receptor (AhR) inhibitor
36. Target 2035 – update on the quest for a probe for every protein
37. Abstract 1646: Discovery and characterization of BAY-6035, a novel benzodiazepine-based SMYD3 inhibitor
38. Front Cover: Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia (ChemMedChem 10/2018)
39. Donated chemical probes for open science
40. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia
41. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties
42. Electronic and steric control of regioselectivities in Rh(I)-catalyzed (5+2) cycloadditions: experiment and theory
43. Author response: Donated chemical probes for open science
44. Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action
45. Abstract 5239: Probing the cancer epigenome: empowering target validation by open innovation
46. Abstract 5084: Potent and isoform-selective ATAD2 bromodomain inhibitor with unprecedented chemical structure and mode of action
47. Abstract 980: BAY-299, a novel chemical probe for in-depth analysis of the function of the bromodomain proteins BRPF2 and TAF1
48. Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
49. Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories
50. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.